Home » FDA Fast Tracks Two New Lung Cancer Drugs
FDA Fast Tracks Two New Lung Cancer Drugs
The FDA has fast-tracked two personalized non-small cell lung cancer drugs from Boehringer Ingelheim and Roche/Astellas, putting the products on track for approval in the third quarter of this year.
PM Live
PM Live
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May